Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing SYR-322 Alone and Combination SYR-322 With Pioglitazone Versus Placebo on Postprandial Lipids in Subjects With Type 2 Diabetes

Trial Profile

Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing SYR-322 Alone and Combination SYR-322 With Pioglitazone Versus Placebo on Postprandial Lipids in Subjects With Type 2 Diabetes

Completed
Phase of Trial: Phase III

Latest Information Update: 01 Apr 2014

At a glance

  • Drugs Alogliptin (Primary) ; Pioglitazone
  • Indications Type 2 diabetes mellitus
  • Focus Pharmacodynamics; Registrational
  • Sponsors Takeda
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 12 Jun 2012 Results presented at the 72nd Annual Scientific Sessions of the American Diabetes Association.
    • 26 Apr 2012 New source identified and integrated (EudraCT2007-000486-38: European Clinical Trials Database).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top